Marinus Pharmaceuticals Comments On Ovid Therapeutics' Patent Challenge And Provides Update On Marinus' Post Grant Review
Marinus Pharmaceuticals Comments On Ovid Therapeutics' Patent Challenge And Provides Update On Marinus' Post Grant Review
Marinus Pharmicals对Ovid Therapeutics的专利质疑发表评论并提供了Marinus拨款后审查的最新情况
affirmed its commitment to defending its patent portfolio amidst an Inter Partes Review (IPR) challenge of U.S. Patent 11,110,100 from Ovid Therapeutics, Inc. filed on March 26, 2024. This challenge relates to a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refractory status epilepticus (RSE). Marinus has multiple patents relating to ganaxolone for the treatment of SE and RSE.
在对Ovid Therapeutics, Inc.于2024年3月26日提交的美国专利11,110,100项的跨方审查（IPR）质疑中，重申了其捍卫其专利组合的承诺。这项挑战与马里纳斯关于使用加那索龙治疗癫痫持续状态（SE）和难治性癫痫持续状态（RSE）的专利有关。Marinus拥有多项与用于治疗SE和RSE的加那索隆相关的专利。